SonoSite (NASDAQ: [[ticker:SONO]])
Cash on hand: $262.9 million
Related Xconomy coverage:
“SonoSite Buys CardioDynamics for $12.3M”
“SonoSite Sales Dip 12 Percent”
Targeted Genetics (NASDAQ: [[ticker:TGEN]])
Cash on hand: $2.5 million
Related Xconomy coverage:
“Targeted Genetics Survives Brush With Death, Sells Gene Therapy IP to Genzyme for $7M”
“Targeted Genetics Cuts Workforce in Half in Bid to Survive Into August”
“Stewart Parker Resigns from Targeted Genetics After Gene Therapy Setbacks”
“Targeted Genetics, Mainstay of Gene Therapy, Faces Likely Shutdown”
“Targeted Genetics’ Legacy: No Cures, But a Generation of Seattle Biotechies”
Trubion Pharmaceuticals (NASDAQ: [[ticker:TRBN]])
Cash on hand: $37.4 million
Related Xconomy coverage:
“Trubion Gets $20M Upfront in Leukemia Drug Partnership With Facet; Shares Boom”
“Trubion Pushing Forward Arthritis Trials, Working to Re-Ignite the Spark for Investors”
“Trubion Cuts One-Fourth of Workforce”
“Pfizer’s Bid For Wyeth Sends Ripples Through Trubion Pharmaceuticals, Seattle Biotechs”
|
||||||
ZymoGenetics (NASDAQ: [[ticker:ZGEN]])
Cash on hand: $118.2 million
Related Xconomy coverage:
“ZymoGenetics Snags $1.1 Billion Partnership With Bristol-Myers For Hepatitis C Drug”
“ZymoGenetics Plays Hardball, Asks FDA to Pull Competing Drug Off Market Because of Safety”
“ZymoGenetics Drug Sales Still Slumping After Full Year on Market”
“ZymoGenetics’ New Boss Sees Parallels to Dark Days at Immunex”
“ZymoGenetics Clamps Down on Losses, Predicts Climbing Recothrom Sales”
“ZymoGenetics Cuts One-Third of Workforce To Hold Onto Cash”
“ZymoGenetics Unloads Drug Candidates to Cut Costs, Spin Off New Company“
